Joseph C. Papa is a seasoned pharmaceutical executive with over three decades of leadership experience in the biopharmaceutical industry. He began his career at Novartis in 1989, where he held progressively senior roles, culminating in his appointment as CEO of Novartis Corporation (U.S.) and Head of North American Pharmaceuticals in 2005. During his 22-year tenure at Novartis, Papa oversaw the launch of blockbuster drugs, drove significant revenue growth, and expanded the company's U.S. market presence through strategic initiatives and acquisitions. In 2011, Papa joined Perrigo Company plc as President and CEO, transforming it into a global leader in over-the-counter consumer self-care products and generic pharmaceuticals. Under his leadership, Perrigo's revenue more than tripled to over $6 billion, market capitalization grew substantially, and the company executed high-profile acquisitions, including the consumer health business of Pfizer and Elan Corporation. His strategic vision and operational expertise earned him recognition as one of the industry's top CEOs, including induction into the Ernst & Young Entrepreneur of the Year Hall of Fame. Appointed President, Chief Executive Officer, and Director of Emergent BioSolutions Inc. in May 2022, Papa is steering the company through a period of strategic refocus on its core strengths in biodefense, vaccines, and therapeutics. Emergent, a key U.S. government partner for medical countermeasures against public health threats like anthrax and smallpox, benefits from Papa's proven track record in regulatory affairs, government contracting, and commercial execution. He continues to drive innovation and operational excellence to enhance national preparedness and global health security.